

REMARKS

Reconsideration of the subject application is requested in view of the above amendments and the following remarks. Claim 1 has been amended for purposes of clarity and to advance prosecution. Claim 62 has been canceled. The above amendment to claim 1 does not represent acquiescence to the Examiner's stated basis for rejection and is made without prejudice to prosecution of any subject matter removed and/or modified by this amendment in a related divisional, continuation or continuation-in-part application. Following the amendments, claims 1-3, 8-12 and 16 remain under examination in the application.

Claims 1-3, 8-12 and 16 stand rejected under 35 U.S.C. § 112, first paragraph, as allegedly failing to comply with the written description requirement. According to the Examiner, one skilled in the art would not recognize from the present disclosure that Applicants were in possession of a genus of cell adhesion modulating agents that modulates cadherin-mediated cell adhesion and comprises an amino acid sequence of SEQ ID NO: 1.

Applicants respectfully traverse this rejection. For purposes of clarity and to advance prosecution, Applicants have amended claim 1 such that the claimed modulating agent comprises the novel cell adhesion recognition (CAR) sequence DWVIP (SEQ ID NO: 3), a species within the previously claimed genus Asp/Glu-Trp-Val-Ile/Val/Met-Pro/Ala-Pro (SEQ ID NO: 1). As set forth in the application as originally filed, the claimed species DWVIP (SEQ ID NO: 3) was shown to be effective in disrupting the cell adhesion properties of ovarian cancer cells (Example 12). Applicants submit that the skilled artisan, in light of this disclosure, would recognize and agree that the presently claimed subject matter was indeed squarely in Applicants' possession at the time the application was filed. All of the requirements necessary to satisfy the written description requirements under 35 U.S.C. § 112, first paragraph, are submitted to have been more than adequately met. Reconsideration of the Examiner's rejections is respectfully requested.

The Director is authorized to charge any additional fees due by way of this Amendment, or credit any overpayment, to our Deposit Account No. 19-1090.

Respectfully submitted,
SEED Intellectual Property Law Group PLLC

/Jeffrey Hundley/
Jeffrey Hundley, Ph.D., Patent Agent
Registration No. 42,676

JEH:ms

701 Fifth Avenue, Suite 5400
Seattle, Washington 98104
Phone: (206) 622-4900
Fax: (206) 682-6031

1093089_1.DOC